No Data
AnGes aims to conclude a sales license agreement for HGF gene therapy products in the USA by the end of 2025.
Anges <4563> is a biotech venture established in 1999 from Osaka Universities, aiming to become the "Global leader in gene medicine" as its long-term vision. In 2020, it made EmendoBio Inc., which develops advanced genome editing technology, a subsidiary. Additionally, in 2021, it opened the "Anges Clinical Research Laboratory," a health inspection laboratory that conducts expanded newborn screening tests for rare genetic diseases in Japan, providing testing service.
AnGes: Interim report.
AnGes: Confirmation letter
AnGes: Financial Report - 26th Term (2024/01/01 - 2024/12/31)
Express News | [Change Report] CANTOR FITZGERALD reported a decrease in the shareholding ratio of ANGEAS (4563.JP) to 13.88%.
Express News | [Change Report] CANTOR FITZGERALD reported a decrease in Shareholding of AnGes (4563.JP) to 14.91%.